- Home
- ADAG vs ATOS Comparison
ADAG vs ATOS Comparison
Compare ADAG & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- ATOS
- Stock Information
- Founded
- ADAG 2011
- ATOS 2009
- Country
- ADAG China
- ATOS United States
- Employees
- ADAG N/A
- ATOS N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ADAG Health Care
- ATOS Health Care
- Exchange
- ADAG Nasdaq
- ATOS Nasdaq
- Market Cap
- ADAG 110.8M
- ATOS 112.7M
- IPO Year
- ADAG 2021
- ATOS 2012
- Fundamental
- Price
- ADAG $1.95
- ATOS $1.02
- Analyst Decision
- ADAG Strong Buy
- ATOS Strong Buy
- Analyst Count
- ADAG 3
- ATOS 3
- Target Price
- ADAG $7.67
- ATOS $6.25
- AVG Volume (30 Days)
- ADAG 60.8K
- ATOS 796.0K
- Earning Date
- ADAG 08-12-2025
- ATOS 11-11-2025
- Dividend Yield
- ADAG N/A
- ATOS N/A
- EPS Growth
- ADAG N/A
- ATOS N/A
- EPS
- ADAG N/A
- ATOS N/A
- Revenue
- ADAG $103,204.00
- ATOS N/A
- Revenue This Year
- ADAG $7,411.34
- ATOS N/A
- Revenue Next Year
- ADAG $28.29
- ATOS N/A
- P/E Ratio
- ADAG N/A
- ATOS N/A
- Revenue Growth
- ADAG N/A
- ATOS N/A
- 52 Week Low
- ADAG $1.33
- ATOS $0.55
- 52 Week High
- ADAG $3.16
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- ADAG 44.56
- ATOS 77.22
- Support Level
- ADAG $1.85
- ATOS $0.86
- Resistance Level
- ADAG $2.06
- ATOS $1.05
- Average True Range (ATR)
- ADAG 0.11
- ATOS 0.05
- MACD
- ADAG -0.01
- ATOS 0.02
- Stochastic Oscillator
- ADAG 26.08
- ATOS 87.06
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.